By Josh White
Date: Thursday 21 Mar 2024
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
By Michele Maatouk
Date: Thursday 29 Feb 2024
(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
By Josh White
Date: Friday 19 Jan 2024
(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.
Currency | UK Pounds |
Share Price | 43.75p |
Change Today | -0.85p |
% Change | -1.91 % |
52 Week High | 159.60 |
52 Week Low | 43.50 |
Volume | 1,446,601 |
Shares Issued | 359.04m |
Market Cap | £157.08m |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 2 |
Neutral | 0 |
Sell | 1 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
10:32 | 1,136 @ 43.70p |
10:29 | 4,000 @ 43.55p |
10:29 | 25,000 @ 43.50p |
10:27 | 6,000 @ 43.55p |
10:27 | 1,700 @ 44.00p |
CEO | Alastair Smith |
CFO | Tony Peter Gardiner |
You are here: research